Immune Recovery in Children after Bone Marrow Transplant Rollo Hoare Supervisors: Robin Callard & Joseph Standing.

Slides:



Advertisements
Similar presentations
AN APPROACH TO THE ANEMIC PATIENT Martin H. Ellis MD Meir Hospital 2007.
Advertisements

Blood and marrow stem cell transplantation A.Basi ADULT HEMATOLOGIST,ONCOLOGIST IRAN UNIVERSITY OF MEDICAL SCIENCES.
Effect of exercise program on natural killer cells in young elderly By Fatemah A. El-shabacy Benha Teaching Hospital.
Modelling Immune reconstitution in paediatric bone marrow transplants London Pharmacometrics Interest Group 1 st March 2013 Rollo Hoare.
Kelsey Cramer. MEET MY AUNT DONATING BONE MARROW.
Quantification of Post- transplantation Chimerism: Algorithm for Correcting Systematic Errors Moshe Israeli Computational Biology Undergraduate Program,
3.7 Organ Transplantation Performed since early 1800’s, 1 st blood transfusions First organ transplant (kidney) 1954 Transplantable organs: heart,liver,lung,pancreas,intestines.
Understanding Cancer Accelerated Biology. Faces of Cancer  You are a doctor interviewing a person (the piece of paper you got on the way in) with cancer.
November  HIV stands for Human Immunodeficiency Virus  It is a virus that attacks the immune system and weakens the body’s ability to fight infection.
DR. YETUNDE T. ISRAEL-AINA PAEDIATRICIAN, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN.
The Berlin Patient and CCR5. Tim Brown: the only man to have been cured of HIV  Brown was diagnosed with HIV in 1995  11 years on antiretroviral therapy.
CMV (Cytomegalovirus) reactivation and immunosupression in allogeneic transplantation Marie Waller Bone Marrow Transplant Coordinator Manchester Royal.
APPLICATIONS OF MONOCLONAL ANTIBODIES
Research done by Dr. Jackleen Raafat Awadallah Hanna Phd of Medical Biochemistry Researcher at Medical Biochemistry Department National Research Center.
Immunology of transplantation. Types of transplantation Autotransplantation –within one organism Allotransplantation- between one species Xenotransplantation-
Liu Baochi Shanghai Public Health Clinical Center affiliated to Fudan University Treating patients with liver cirrhosis by BMT.
Leukemia Omidreza keshavarz Ahmad darvishi Nursing 86 Hormozgan university of medical sciences Bandarabbas faculty of nursing،midwifery and paramedical.
HAEMATOPOIETIC STEM ELL TRANSPLANTATION (HSCT) A process in which abnormal, malignant, or non- functioning marrow cells are replaced with normal marrow.
Beginning of the chapter HIV resistance and genetics (HIV RESISTANCE SENSOR) 57.
Bone Marrow Donation Zach Siefker HNRS 1010.
Date of download: 6/22/2016 From: Acquired Aplastic Anemia Ann Intern Med. 2002;136(7): doi: / Venn diagram.
Abstract Immune Reconstitution and Clinical Outcome After Donor Lymphocyte Infusion for Relapsed Disease After Reduced-Intensity Allogeneic Hematopoietic.
Children with Cancer UK
Immunotherapy with CD19 CAR redirected T-cells for high risk, relapsed paediatric CD19+ acute lymphoblastic leukaemia (ALL) and other haematological malignancies.
RIC UCBT Transplantation of Umbilical Cord Blood from Unrelated Donors in Patients with Haematological Diseases using a Reduced Intensity Conditioning.
Utilization and Outcome of Bone Marrow Transplantation in Children with Sickle Cell Disease: A Pediatric Health Information System Database Analysis 
Tissue and Organ Transplantation
Mild preconditioning and low-level engraftment confer methotrexate resistance in mice transplanted with marrow expressing drug-resistant dihydrofolate.
Umbilical Cord Blood as an Alternative Source of Reduced-Intensity Hematopoietic Stem Cell Transplantation for Chronic Epstein-Barr Virus–Associated T.
Clinical response to F16-IL2 and LDAC in patients with AML bone marrow involvement. Clinical response to F16-IL2 and LDAC in patients with AML bone marrow.
Alternative Allogeneic Donor Sources for Transplantation for Childhood Diseases: Unrelated Cord Blood and Haploidentical Family Donors  Mitchell S. Cairo,
Immunotherapy for Pediatric Cancer
Il trapianto allogenico da donatore alternativo dopo condizionamento a ridotta intensità Alessandro Rambaldi.
Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation by George E. Georges, Rainer Storb, Jennifer.
PREDICTIVE FACTORS AFFECTING THE OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION USING RIC REGIMENS: EXPERIENCE FROM A SINGLE CENTRE Dott.ssa M. Medeot.
Figure 1 Outline of the AHSCT procedure
Vaccination of Children following Allogeneic Stem Cell Transplantation
Assessment of Allogeneic HCT in Older Patients with AML and MDS: A CIBMTR Analysis McClune B et al. ASCO/ASH Symposium 2009;The Best of ASH Special & Plenary.
Today (2/23/16) Learning objectives:
Donor-Derived Natural Killer Cells Infused after Human Leukocyte Antigen– Haploidentical Hematopoietic Cell Transplantation: A Dose-Escalation Study  Inpyo.
Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8+ T-cell count on day +14 as a predictor.
Impact of Serotherapy on Immune Reconstitution and Survival Outcomes After Stem Cell Transplantations in Children: Thymoglobulin Versus Alemtuzumab  Laura.
Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-
Reduced-Intensity Allogeneic Stem Cell Transplantation in Adults and Children with Malignant and Nonmalignant Diseases: End of the Beginning and Future.
Figure 2 Components of each transplantation platform
A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide,
Serious Infection Risk and Immune Recovery after Double-Unit Cord Blood Transplantation Without Antithymocyte Globulin  Craig Sauter, Michelle Abboud,
Donor KIR Genes 2DL5A, 2DS1 and 3DS1 Are Associated with a Reduced Rate of Leukemia Relapse After HLA-Identical Sibling Stem Cell Transplantation for.
TIM-1 Blockade of the Donor Graft Provides Protection Against Lethal Gvhd  Bettina P. Iliopoulou, PhD, Katie Hsu, MS, Antonio Pierini, MD, Gordon J. Freeman,
Recent Decrease in Acute Graft-versus-Host Disease in Children with Leukemia Receiving Unrelated Donor Bone Marrow Transplants  Stella M. Davies, Dan.
Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma  Jessica Rueff, Michael Medinger,
Should Methotrexate plus Calcineurin Inhibitors Be Considered Standard of Care for Prophylaxis of acute Graft-versus-Host Disease?  Rainer Storb, Joseph.
Supplemental Figure untreated Rituximab Alemtuzumab
A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation, and Onset of Graft-versus-Host Disease in.
Kasiani C. Myers, Stella M. Davies 
Relationship of CMV Reactivation and Rabbit Antithymocyte Globulin Administration in Allogeneic Stem Cell Transplant Patients  LeAnne Kennedy, Marie Cavalier,
Allogeneic Transplantation for Pediatric Acute Lymphoblastic Leukemia: The Emerging Role of Peritransplantation Minimal Residual Disease/Chimerism Monitoring.
Biology of Blood and Marrow Transplantation
Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant.
Total and Active Rabbit Antithymocyte Globulin (rATG;Thymoglobulin®) Pharmacokinetics in Pediatric Patients Undergoing Unrelated Donor Bone Marrow Transplantation 
by Shannon L. Maude, David T. Teachey, David L. Porter, and Stephan A
Filgrastim enhances T-cell clearance by antithymocyte globulin exposure after unrelated cord blood transplantation by Coco de Koning, Julie-Anne Gabelich,
A Modified Haploidentical Nonmyeloablative Transplantation without T Cell Depletion for High-Risk Acute Leukemia: Successful Engraftment and Mild GVHD 
Eliane Gluckman  Experimental Hematology 
Optimization of Therapy for Severe Aplastic Anemia Based on Clinical, Biologic, and Treatment Response Parameters: Conclusions of an International Working.
Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation  Celia Grosskreutz,
Volume 17, Issue 11, Pages (November 2009)
Mary Eapen  Biology of Blood and Marrow Transplantation 
How I vaccinate blood and marrow transplant recipients
Diagnoses in patients with TA-GVHD.
Presentation transcript:

Immune Recovery in Children after Bone Marrow Transplant Rollo Hoare Supervisors: Robin Callard & Joseph Standing

Bone Marrow Transplant (BMT) BMT done post leukemia or other immune system failure Before BMT patients undergo conditioning during which all lymphocytes in the body may be killed We are looking at the recovery of the immune system after BMT In particular the concentration of CD4 in the blood

The aim of the project 1.Build a model for the CD4 cell count recovery 2.Fit the model to the data (CD4 count time series) 3.Add parameters related to covariates 4.Analyse results of included covariates

The aim of the project 1.Build a model for the CD4 cell count recovery 2.Fit the model to the data (CD4 count time series) 3.Add parameters related to covariates 4.Analyse results of included covariates

1. The Model Start with an exponential model: asy int Parameters asy = asymptote int = intercept c = rate of change

The aim of the project 1.Build a model for the CD4 cell count recovery 2.Fit the model to the data (CD4 count time series) 3.Add parameters related to covariates 4.Analyse results of included covariates

2. Fit model to data a) Age adjustment CD4 count drops non-linearly with age in healthy children

2. Fit model to data NLME Modelling

The aim of the project 1.Build a model for the CD4 cell count recovery 2.Fit the model to the data (CD4 count time series) 3.Add parameters related to covariates 4.Analyse results of included covariates

3. Add covariates Multivariate analysis: we add covariate parameters into the model for: -BMT Age -Sex -BMT Number -Donor type -Donor cells type -Leukaemia -HCMV -EBV -Alem/anti-CD45/ATG -Total body irradiation -Cyclosporine -Methotrexate -Mycophenolate -Prednisone -Muromonab -No conditioning -Reduced conditioning -Chimerism

3. Diagnostic Plots

The aim of the project 1.Build a model for the CD4 cell count recovery 2.Fit the model to the data (CD4 count time series) 3.Add parameters related to covariates 4.Analyse results of included covariates

4. Results After SCM, we included the following covariates: Int: -Alemtuzumab/Anti-CD45/Anti-thymocyte Globulin -Leukaemia -Donor type Asy: -HCMV -No conditioning c: -Mycophenolate

4. Results Int: Alem/anti-CD45/ATG

4. Results Int: Leukaemia

4. Results Int: Donor type

4. Results Asy: HCMV

4. Results Asy: Conditioning

4. Results C: Mycophenolate

Next Steps Include age adjustment in the model rather than pre- adjustment -Linear -Free exponential -Fixed exponential -Fixed exponential with ratio Or use another form of age adjustment -Square root ratio -Fourth root ratio Add in further covariates for conditioning drugs and diagnoses Look at dosage information

Next Steps Include age in model: Linear ASY = THETA(1) + THETA(2) * (3650-AGE)

Next Steps Include age in model: Linear ASY = THETA(1) + THETA(2) * (3650-AGE)

Next Steps Include age in model: Free exponential ASY = THETA(1) +THETA(2) * EXP(-THETA(3)*AGE)

Next Steps Include age in model: Free exponential ASY = THETA(1) +THETA(2) * EXP(-THETA(3)*AGE)

Next Steps Include age in model: Fixed exponential ASY = * EXP( *AGE)

Next Steps Include age in model: Fixed exponential ASY = * EXP( *AGE)

Next Steps Include age in model: Fixed exponential with ratio ASY = THETA(1) * ( * EXP( *AGE))

Next Steps Include age in model: Fixed exponential with ratio ASY = THETA(1) * ( * EXP( *AGE))

Next Steps Age adjustment: Fourth root ratio

Next Steps Additional Covariates to be tested -BMT Failure -Alemtuzumab -Anti CD-45 -Anti-thymocyte globulin -Busulphan -Cyclosporine (Conditioning) -Melphalan -Fludarabine -Treosulphan -Diagnosis -Edited EBV -Edited HCMV -Edited donor cells -Edited donor type

Conclusion We have modelled the CD4 count recovery of children post BMT using the logratio We have found the following covariates affect recovery: - Int: Alem/anti-CD45/ATG, Leukaemia, donor type - Asy: Conditioning, HCMV - c: mycophenolate More work needs to be done to ascertain the reliability of these results.

Questions??